Nurix Therapeutics, Inc.

NasdaqGM:NRIX Stock Report

Market Cap: US$1.4b

Nurix Therapeutics Future Growth

Future criteria checks 2/6

Nurix Therapeutics is forecast to grow earnings and revenue by 5.9% and 38.5% per annum respectively. EPS is expected to grow by 13.9% per annum. Return on equity is forecast to be -75% in 3 years.

Key information

5.9%

Earnings growth rate

13.9%

EPS growth rate

Biotechs earnings growth27.6%
Revenue growth rate38.5%
Future return on equity-75.0%
Analyst coverage

Good

Last updated19 Dec 2024

Recent future growth updates

Recent updates

Subdued Growth No Barrier To Nurix Therapeutics, Inc. (NASDAQ:NRIX) With Shares Advancing 25%

Nov 07
Subdued Growth No Barrier To Nurix Therapeutics, Inc. (NASDAQ:NRIX) With Shares Advancing 25%

Companies Like Nurix Therapeutics (NASDAQ:NRIX) Are In A Position To Invest In Growth

Oct 31
Companies Like Nurix Therapeutics (NASDAQ:NRIX) Are In A Position To Invest In Growth

Nurix: An Attractive Early-Stage Biotech Play

Oct 08

Unpleasant Surprises Could Be In Store For Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) Shares

Sep 07
Unpleasant Surprises Could Be In Store For Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) Shares

Nurix Therapeutics: Promising Science, Major Collaborations, Undifferentiated Data

Sep 04

Nurix Therapeutics (NASDAQ:NRIX) Is In A Good Position To Deliver On Growth Plans

Jul 15
Nurix Therapeutics (NASDAQ:NRIX) Is In A Good Position To Deliver On Growth Plans

Nurix Therapeutics: Protein Deg Specialist's Latest Data Establishes Bull Case

Jun 19

What Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 26% Share Price Gain Is Not Telling You

May 29
What Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 26% Share Price Gain Is Not Telling You

Nurix Therapeutics Advances Promising Protein Degraders For B-Cell Malignancies

Apr 15

Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 28% Price Boost Is Out Of Tune With Revenues

Apr 14
Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 28% Price Boost Is Out Of Tune With Revenues

Improved Revenues Required Before Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Find Their Feet

Feb 20
Improved Revenues Required Before Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Find Their Feet

Nurix Therapeutics: Recovering Thanks To ASH, But I Think It's Priced Just Right For Now

Jan 16

Here's Why We're Watching Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Situation

Dec 29
Here's Why We're Watching Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Situation

Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 29% Dip In Price Shows Sentiment Is Matching Revenues

Oct 14
Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 29% Dip In Price Shows Sentiment Is Matching Revenues

Broker Revenue Forecasts For Nurix Therapeutics, Inc. (NASDAQ:NRIX) Are Surging Higher

Oct 13
Broker Revenue Forecasts For Nurix Therapeutics, Inc. (NASDAQ:NRIX) Are Surging Higher

Here's Why We're Watching Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Situation

Sep 30
Here's Why We're Watching Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Situation

Party Time: Brokers Just Made Major Increases To Their Nurix Therapeutics, Inc. (NASDAQ:NRIX) Earnings Forecasts

Apr 18
Party Time: Brokers Just Made Major Increases To Their Nurix Therapeutics, Inc. (NASDAQ:NRIX) Earnings Forecasts

We Think Nurix Therapeutics (NASDAQ:NRIX) Needs To Drive Business Growth Carefully

Apr 15
We Think Nurix Therapeutics (NASDAQ:NRIX) Needs To Drive Business Growth Carefully

We're Keeping An Eye On Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Rate

Nov 28
We're Keeping An Eye On Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Rate

Nurix Therapeutics GAAP EPS of -$0.90 beats by $0.07, revenue of $10.79M misses by $1.29M

Oct 06

Nurix Therapeutics GAAP EPS of -$1.01 misses by $0.02, revenue of $11.43M beats by $0.93M

Jul 07

FDA approves expansion of Nurix Therapeutics' phase 1 trial of NX-1607 into the U.S.

Jun 30

We Think Nurix Therapeutics (NASDAQ:NRIX) Needs To Drive Business Growth Carefully

Jun 21
We Think Nurix Therapeutics (NASDAQ:NRIX) Needs To Drive Business Growth Carefully

We Think Nurix Therapeutics (NASDAQ:NRIX) Can Afford To Drive Business Growth

Mar 07
We Think Nurix Therapeutics (NASDAQ:NRIX) Can Afford To Drive Business Growth

Nurix: Advancing Targeted Protein Modulation Therapies

Nov 21

Companies Like Nurix Therapeutics (NASDAQ:NRIX) Can Afford To Invest In Growth

Nov 21
Companies Like Nurix Therapeutics (NASDAQ:NRIX) Can Afford To Invest In Growth

Earnings and Revenue Growth Forecasts

NasdaqGM:NRIX - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
11/30/202789-259-257-2169
11/30/202663-256-226-20613
11/30/202556-221-205-17116
11/30/202455-187-173-16016
8/31/202456-177-107-97N/A
5/31/202462-165-106-96N/A
2/29/202481-145-84-75N/A
11/30/202377-144-90-81N/A
8/31/202369-149-154-146N/A
5/31/202361-157-161-151N/A
2/28/202342-179-177-166N/A
11/30/202239-180-172-160N/A
8/31/202239-171-163-153N/A
5/31/202239-154-145-136N/A
2/28/202234-135-143-135N/A
11/30/202130-117-90-84N/A
8/31/202129-99-80-74N/A
5/31/202123-89-56-50N/A
2/28/202120-63-38-33N/A
11/30/202018-43-50N/A
8/31/202013-3738N/A
5/31/202019-214750N/A
2/29/202025-244951N/A
11/30/201931-22-11N/A
11/30/201837-9-33-32N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: NRIX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: NRIX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: NRIX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: NRIX's revenue (38.5% per year) is forecast to grow faster than the US market (9.1% per year).

High Growth Revenue: NRIX's revenue (38.5% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: NRIX is forecast to be unprofitable in 3 years.

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 15:53
End of Day Share Price 2024/12/20 00:00
Earnings2024/08/31
Annual Earnings2023/11/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Nurix Therapeutics, Inc. is covered by 22 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Brian SkorneyBaird
Joel BeattyBaird
Peter LawsonBarclays